Open AccessCombined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients WithRASWild-Type Advanced Colorectal Cancer
Author(s) -
Jenny F. Seligmann,
Faye Elliott,
Susan D. Richman,
Bart Jacobs,
Gemma Hemmings,
Sarah Brown,
Jennifer H. Barrett,
Sabine Tejpar,
Philip Quirke,
Michel Seymour
Publication year - 2016
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2015.6065
Subject(s) - epiregulin , amphiregulin , medicine , panitumumab , oncology , kras , colorectal cancer , irinotecan , predictive marker , biomarker , epidermal growth factor receptor , cancer , biology , biochemistry
RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may represent a much-needed additional predictive marker for these drugs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom